MedTrace Logo

Effect of Meningococcal Conjugate Vaccine on Meningococcal Carriage

NCT00119080 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 4000

Last updated 2007-03-19

No results posted yet for this study

Summary

The purpose of this study is to determine whether the new meningococcal conjugate vaccine (MCV4) can reduce asymptomatic carriage of meningococcal bacteria, and thus decrease the transmission of these bacteria in the population.

Conditions

Interventions

BIOLOGICAL

meningococcal conjugate vaccine (Menactra)

Sponsors & Collaborators

Principal Investigators

  • Eric Stern, MD · Centers for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-08-31
Completion
2007-05-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00119080 on ClinicalTrials.gov